Skip to main content

Drug Interactions between levacetylleucine and Nubeqa

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

darolutamide levacetylleucine

Applies to: Nubeqa (darolutamide) and levacetylleucine

MONITOR: Coadministration with levacetylleucine may increase the plasma concentrations (AUC) and adverse effects of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter. Levacetylleucine is a P-gp inhibitor in vitro. However, clinical data are not available.

MANAGEMENT: If coadministration is clinically necessary, more frequent clinical monitoring for P-gp substrate related adverse reactions is advised and dose adjustments may be required, particularly when levacetylleucine is initiated or withdrawn from concomitant therapy. Consultation with package labeling of the concomitant medication may be advisable.

References (1)
  1. (2024) "Product Information. Aqneursa (levacetylleucine)." IntraBio Inc

Drug and food interactions

Moderate

darolutamide food

Applies to: Nubeqa (darolutamide)

ADJUST DOSING INTERVAL: Food enhances the oral absorption of darolutamide. According to the prescribing information, bioavailability of darolutamide increased by 2.0 to 2.5-fold when administered with food. A similar increase in exposure was observed for the active metabolite keto-darolutamide.

MANAGEMENT: Darolutamide should be administered with food.

References (1)
  1. (2019) "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer